Pimonidazole

PreclinicalSmall molecule

UUniversity Health Network, Toronto

Pimonidazole is one of 56 small molecule programs targeting Melanoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

SarcomaActive, not recruiting

MelanomaPreclinical

Active, not recruiting

SarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

177 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

93 2

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 3

39 3

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 4

Taxol

Teva

Phase 3

13 5

Mektovi

Pfizer

Phase 3

12 6

Tecentriq

Roche

Phase 3

11 7

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 8

Lenvima

Eisai

Phase 3

9 9

Libtayo

Regeneron

Phase 3

5 10

Opdualag

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Melanoma

NCT06831071

Q1 2028

PreclinicalActive, not recruiting

Prostate Cancer

NCT02095249

Recruiting

Melanoma

NCT04658303

Q4 2028

PreclinicalActive, not recruiting

Sarcoma

NCT03418818

Clinical

Trials by Indication[1]

Melanoma2 trials

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Recruiting·YYana Najjar··NCT04658303·20 enrolled

Evaluation of Hypoxia in Primary Melanoma

Recruiting·YYana Najjar··NCT06831071·50 enrolled

Hypoxia2 trials

Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer

Suspended·SSunnybrook Health Sciences Centre·Phase 1/2·NCT03181035·10 enrolled

Hypoxia Analysis in Head and/or Neck Cancer

Unknown status·MMarius Gustav Bredell·Phase 2·NCT02414048·10 enrolled

Prostate Cancer2 trials

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01992042·33 enrolled

Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer

Active, not recruiting·UUniversity Health Network, Toronto·Preclinical·NCT02095249·39 enrolled

Pancreatic Cancer1 trial

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03718650

Sarcoma1 trial

A Prospective Study of Hypoxia Imaging in Patients With Soft Tissue Sarcoma Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Combination With MRI

Active, not recruiting·UUniversity Health Network, Toronto·Preclinical·NCT03418818·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Pimonidazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pimonidazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pimonidazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Health Network, Toronto

Pimonidazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Melanoma2 trials

Hypoxia2 trials

Prostate Cancer2 trials

Pancreatic Cancer1 trial

Sarcoma1 trial

References

Drug Info

Quick Facts

Related News